<div id="readability-page-1"><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) is anticipated to post its  Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Taysha Gene Therapies to post earnings of ($0.10) per share and revenue of $0.7560 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.</p><ul><li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li></ul><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million.  On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. </p><div><p><span></span><span>Get <strong>Taysha Gene Therapies</strong> alerts:</span></p></div><h2>Taysha Gene Therapies Stock Down 0.9%</h2><p>TSHA opened at $6.33 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. The company's 50-day moving average is $4.95 and its 200 day moving average is $4.89. Taysha Gene Therapies has a fifty-two week low of $1.85 and a fifty-two week high of $6.76. The firm has a market capitalization of $1.82 billion, a P/E ratio of -18.62 and a beta of 1.25. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>3 Small-Cap Stocks For Your Fall Shopping List</li></ul><p>A number of research firms recently weighed in on TSHA. Wall Street Zen raised shares of Taysha Gene Therapies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, March 21st. Needham &amp; Company LLC raised their price target on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 19th. Chardan Capital  reissued a &#34;buy&#34; rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Finally, Truist Financial raised shares of Taysha Gene Therapies to a &#34;strong-buy&#34; rating in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued  a Buy rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average target price of $11.64.</p><p><b>Read Our Latest Stock Analysis on Taysha Gene Therapies</b></p><h2>Insider Buying and Selling</h2><p>In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider owned 1,136,410 shares of the company's stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own  3.78% of the company's stock. </p><h2>Institutional Trading of Taysha Gene Therapies</h2><p>Hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc bought a new stake in  Taysha Gene Therapies in the second quarter worth about $29,000.  E Fund Management Co. Ltd. bought a new stake in  Taysha Gene Therapies in the second quarter worth about $31,000.  Tower Research Capital LLC TRC raised its position in  Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock worth $41,000 after acquiring an additional 10,742 shares during the period.  BNP Paribas Financial Markets raised its position in  Taysha Gene Therapies by 51.9% in the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company's stock worth $43,000 after acquiring an additional 6,350 shares during the period.  Finally, Caitong International Asset Management Co. Ltd raised its position in  Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock worth $43,000 after acquiring an additional 4,607 shares during the period. Institutional investors own  77.70% of the company's stock. </p><h2>Taysha Gene Therapies Company Profile</h2> (Get Free Report)<p>Taysha Gene Therapies, Inc <span>NASDAQ: TSHA<span></span></span> is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.  </p><p>Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.</p><h2>Read More</h2><ul><li>Five stocks we like better than Taysha Gene Therapies</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p><p>While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TSHA

ARKG

<p>Taysha Gene Therapies (NASDAQ:TSHA) is set to release its Q1 2026 earnings on May 6, with analysts predicting a loss of $0.10 per share and revenue of $0.756 million. The company previously reported a loss of $0.08 per share for Q1 2025, exceeding expectations. TSHA's stock is currently down 0.9%, with a market cap of $1.82 billion. Recent analyst ratings include a mix of buy and hold recommendations, with an average target price of $11.64. Insider trading activity shows a significant sale by an executive, while institutional ownership stands at 77.70%.</p>

Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday